Tirzepatide protects against hepatic oxidative stress in high-fat induced obesity in male rats

Background Obesity is a prevalent health issue that affects people of all ages at a high rate. Tirzepatide (TZP) is a hypoglycemic medication that acts as a dual antagonist for both the GIP-1 and GIP receptors. Previous reports have shown that TZP treatment demonstrated substantial weight reduction as well as lipid-modulating effects in obese and overweight individuals. Objective The aim from this study is to examine the potential protective effect of TZP on oxidative stress status and HFD induced obesity in male rats. Methods This research employed a total of 28 adult male Sprague-Dawley rats. Normal control group involved seven rats fed a regular diet, while the other rats received a high-fat diet (HFD). Obese rats separated into three groups after eight weeks of HFD: obesity, tirzepatide (10 nmol/kg) s.c, and vehicle groups, and treated for four weeks. Data regarding body weight, blood glucose, and lipid profile, as well as the levels of SOD and MDS in the liver tissue were obtained. Results The results have demonstrated that TZP-treated obese rats exhibited significantly reduced body weight, blood glucose levels, TG and VLDL. Additionally, liver specimens from TZP group showed increased content of SOD enzyme compared to obese untreated rats. Conclusion Treating obese rats with TZP improved body weight, blood glucose lipid profile and elevating the level of the antioxidant defense.